Investor Overview

Corporate Profile


Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK."

Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic... 
Read More >

Stock Information

NASDAQ :  ITEK (Common Stock)
$1.58
 - 0.03 (1.25%)
Data as of 02/22/17 11:16 a.m. ET
Data provided by Nasdaq. Minimum 15 minute delay
Refresh quote
Stock chart for: ITEK.OQ.  Currently trading at $1.58 with a 52 week high of $10.90 and a 52 week low of $1.50.